top of page
About the Disease

POMPE DISEASE

About the Disease

About our Patient Care

Pompe disease is an inherited disorder caused by the buildup of glycogen, a complex sugar, in the body's cells, which impairs the ability for affected organs, tissues, and muscles to function normally.

​

Several different clinical types of Pompe disease have been identified.

​

Classic form,  infantile-onset

The classic form of Pompe disease begins within a few months of birth. Infants with this disorder typically experience muscle weakness, poor muscle tone, an enlarged liver, and heart defects. Affected infants may also fail to gain weight and grow at the expected rate and have breathing problems. If untreated, this form of Pompe disease leads to death from heart failure in the first year of life.

​

Non-classic form, infantile-onset

The non-classic form of Pompe disease usually appears by age 1 and is characterized by delayed motor skills and progressive muscle weakness. The heart may be abnormally large, but affected individuals usually do not experience heart failure. The muscle weakness in this disorder leads to serious breathing problems, and most children with non-classic infantile-onset Pompe disease live only into early childhood.

​

Late-onset

The late-onset form of Pompe disease may not become apparent until later in childhood, adolescence, or adulthood and is usually milder than the infantile-onset forms of this disorder and is less likely to involve the heart. Most individuals with this type experience progressive muscle weakness, especially in the legs and the trunk, including the muscles that control breathing. As the disorder progresses, breathing problems can lead to respiratory failure.

​

​

About our Patient Care

Our dedicated Care Team will work with the physician's office and insurance on a patient's behalf so that our patients have more time to focus on their treatment and quality of life. We are here to listen, provide 

counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.

​

As part of treatment, we provide:

​

Dedicated Care Team

 

We provide prescribers and patients with a dedicated care team for each of our disease state programs. This includes a primary pharmacy contact, clinical education, side-effects management, scheduled refill calls, and a direct phone, fax and email address.

​

​

In-Home Patient- and Family-Centric Care

 

We administer a nationwide nursing network, allowing patients to pursue in-home treatment or receive training on self-administrated drugs. Our nurses are ideally positioned to establish a partnership with patients and their families in order to provide clinical education and coaching that strengthen the patient's capacity to achieve therapy goals.

​

​

Shipping and Coordination of Care

 

We provide free overnight delivery of medications and necessary medical supplies and manage the coordination of care between prescribers, sites of care, nurses and patients to ensure dispenses and drug delivery align with the date and location of service.

​

​

​

Financial Assistance

​

We successfully identify and assist enrolling patients into any and all manufacturer co-pay and foundation support programs in order to minimize a potential financial burden to patients given the high-cost of specialty medications.

​

​

Supported Treatments

24/7/365 Access to a Pharmacist

 

We provide prescribers and patients access to a pharmacist 24/7/365 to ensure patients are always cared for.

​

​

  • Berinert (C1 esterase inhibitor)
    Brand Name | Berinert Manufacturer | CSL Berhing Route of Administration | Intravenous (IV) injection Approved Indication | Treatment of acute abdominal, facial, or laryngeal HAE attacks in adult and pediatric patients Self-Administration | Yes, after training Product Website | www.berinert.com
  • Cinryze (C1 esterase inhibitor)
    Brand Name | Cinryze Manufacturer | Shire Route of Administration | Intravenous (IV) injection Approved Indication | Routine prophylaxis against angioedema attacks in patients with HAE Self-Administration | Yes, after training Product Website | www.cinryze.com
  • Firazyr (icatibant)
    Brand Name | Firazyr Manufacturer | Shire Route of Administration | Subcutaneous (SC) injection Approved Indication | Treatment of acute attacks of HAE in adults 18 years of age and older Self-Administration | Yes, after training Product Website | www.firazyr.com
  • Haegarda (C1 esterase inhibitor)
    Brand Name | Haegarda Manufacturer | CSL Behring Route of Administration | Subcutaneous Approved Indication | For routine prophylaxis to prevent HAE attacks in adolescent and adult patients. Self-Administration | Yes Product Website | www.haegarda.com
  • Kalbitor (ecallantide)
    Brand Name | Kalbitor Manufacturer | Dyax Corp Route of Administration | Subcutaneous injection Approved Indication | For routine prophylaxis to prevent HAE attacks in adolescent and adult patients. Self-Administration | No Product Website | www.kalbitor.com
  • Ruconest (C1 esterase inhibitor)
    Brand Name | Rocunest Manufacturer | Pharming N.V. Route of Administration | Intravenous (IV) injection Approved Indication | Treatment of acute attacks of HAE in adult and adolescent patients. Self-Administration | Yes, after training Product Website | www.ruconest.com
  • Takhzyro (lanadelumab-flyo)
    Brand Name | Takhzyro Manufacturer | Shire Route of Administration | Subcutaneous injection Approved Indication | Prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years of age and older Self-Administration | Yes, after training Product Website | www.takhzyro.com

Supported Treatments

Partnering with Prescribers

Partnering with Prescribers

Licensed prescribers can submit a completed enrollment form directly to our Admission team. We will begin the process and communicate with your office every step of the way.

Send Us A Script

bottom of page